Allergy Therapeutics (GB:AGY) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Allergy Therapeutics has secured an additional £5 million from its amended loan facility with major shareholders, extending its financial runway into late September. The company still has access to £12.5 million of uncommitted funds and is exploring further financing options to support operations and its development pipeline.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue